Literature DB >> 26788193

Characterization of the expression and clinical features of epidermal growth factor receptor and vascular endothelial growth factor receptor-2 in esophageal carcinoma.

Madiniyat Niyaz1, Jurat Anwer2, Hui Liu1, Liwei Zhang2, Ilyar Shayhedin2, Idiris Awut2.   

Abstract

The present study aimed to understand the expression characteristics of epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor-2 (VEGFR-2) in individuals of Uygur, Han and Kazak ethnicity with esophageal carcinoma in Xinjiang (China) and their interrelation analysis, and to investigate the expression differences in these genes between esophageal carcinoma and pericarcinoma tissue samples, and between the three ethnic groups. The expression levels of EGFR and VEGFR-2 from 119 pairs of esophageal carcinoma tissue and corresponding pericarcinoma tissue from Uygur, Han and Kazak patients with esophageal carcinoma were detected by immunohistochemistry following surgical resection, and an additional five carcinoma in situ specimens were also tested. The relative expression was analyzed among the ethnic groups and clinicopathological parameters. The positive rate of EGFR in esophageal carcinoma tissue from patients of Uygur, Han and Kazak heritage was 70.73, 68.42 and 67.5%, respectively. For VEGFR-2 the positive rate was 73.17, 68.42 and 67.5%, respectively. No significant difference was detected in their expression between the three ethnic groups (P>0.05); however, EGFR and VEGFR-2 overexpression were correlated with lymph node metastasis (P<0.05). VEGF expression was also correlated with the expression of VEGFR-2 in esophageal carcinoma tissues. EGFR was positive in carcinoma in situ samples, while VEGFR-2 was negative. The overexpression of EGFR is therefore an early event and may have a significant role in the progression of esophageal carcinoma pathogenesis. EGFR overexpression may correlate with the expression of VEGFR-2 in esophageal cancer. These results may aid the early diagnosis of esophageal cancer, and the development of individual target treatment in the future.

Entities:  

Keywords:  epidermal growth factor receptor; esophageal carcinoma; immunohistochemistry; multi-nationalities; vascular endothelial growth factor receptor-2

Year:  2015        PMID: 26788193      PMCID: PMC4665312          DOI: 10.3892/ol.2015.3747

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  17 in total

1.  Lapatinib inhibits receptor phosphorylation and cell growth and enhances antibody-dependent cellular cytotoxicity of EGFR- and HER2-overexpressing esophageal cancer cell lines.

Authors:  Kousaku Mimura; Koji Kono; Takanori Maruyama; Mitsuaki Watanabe; Shinichiro Izawa; Shugo Shiba; Yoshiki Mizukami; Yoshihiko Kawaguchi; Masayuki Inoue; Tetsuo Kono; Aniruddha Choudhury; Rolf Kiessling; Hideki Fujii
Journal:  Int J Cancer       Date:  2011-04-08       Impact factor: 7.396

2.  Increased VEGFR-2 gene copy is associated with chemoresistance and shorter survival in patients with non-small-cell lung carcinoma who receive adjuvant chemotherapy.

Authors:  Fei Yang; Ximing Tang; Erick Riquelme; Carmen Behrens; Monique B Nilsson; Uma Giri; Marileila Varella-Garcia; Lauren A Byers; Heather Y Lin; Jing Wang; Maria G Raso; Luc Girard; Kevin Coombes; J Jack Lee; Roy S Herbst; John D Minna; John V Heymach; Ignacio I Wistuba
Journal:  Cancer Res       Date:  2011-07-01       Impact factor: 12.701

3.  Global cancer statistics, 2002.

Authors:  D Max Parkin; Freddie Bray; J Ferlay; Paola Pisani
Journal:  CA Cancer J Clin       Date:  2005 Mar-Apr       Impact factor: 508.702

4.  Epidermal growth factor receptor mediates increased cell proliferation, migration, and aggregation in esophageal keratinocytes in vitro and in vivo.

Authors:  Claudia D Andl; Takaaki Mizushima; Hiroshi Nakagawa; Kenji Oyama; Hideki Harada; Katerina Chruma; Meenhard Herlyn; Anil K Rustgi
Journal:  J Biol Chem       Date:  2002-11-14       Impact factor: 5.157

5.  Expression of EGFR and LRIG proteins in oesophageal carcinoma with emphasis on patient survival and cellular chemosensitivity.

Authors:  Xuping Wu; Håkan Hedman; Michael Bergqvist; Stefan Bergström; Roger Henriksson; Joachim Gullbo; Johan Lennartsson; Patrik Hesselius; Simon Ekman
Journal:  Acta Oncol       Date:  2011-03-18       Impact factor: 4.089

6.  EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus.

Authors:  Mitsuhiko Hanawa; Shioto Suzuki; Yoh Dobashi; Tetsu Yamane; Koji Kono; Nobuyuki Enomoto; Akishi Ooi
Journal:  Int J Cancer       Date:  2006-03-01       Impact factor: 7.396

Review 7.  Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab.

Authors:  Toni M Brand; Mari Iida; Deric L Wheeler
Journal:  Cancer Biol Ther       Date:  2011-05-01       Impact factor: 4.742

8.  Evaluation of prognostic factors of esophageal squamous cell carcinoma (stage II-III) after concurrent chemoradiotherapy using biopsy specimens.

Authors:  Takayuki Kii; Hiroya Takiuchi; Shinichiro Kawabe; Masahiro Gotoh; Shunsuke Ohta; Toshimitsu Tanaka; Shin Kuwakado; Hitoshi Nishitani; Ken-ichi Katsu
Journal:  Jpn J Clin Oncol       Date:  2007-08-20       Impact factor: 3.019

9.  Diffuse EGFR staining is associated with reduced overall survival in locally advanced oesophageal squamous cell cancer.

Authors:  L Gibault; J-P Metges; V Conan-Charlet; P Lozac'h; M Robaszkiewicz; C Bessaguet; N Lagarde; A Volant
Journal:  Br J Cancer       Date:  2005-07-11       Impact factor: 7.640

10.  EGFR gene alterations as a prognostic biomarker in advanced esophageal squamous cell carcinoma.

Authors:  Kazuhiro Kaneko; Yosuke Kumekawa; Reiko Makino; Hisako Nozawa; Yuichi Hirayama; Mari Kogo; Kazuo Konishi; Atsushi Katagiri; Yutaro Kubota; Takashi Muramoto; Miki Kushima; Tohru Ohmori; Tsunehiro Oyama; Norio Kagawa; Atsushi Ohtsu; Michio Imawari
Journal:  Front Biosci (Landmark Ed)       Date:  2010-01-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.